354 related articles for article (PubMed ID: 31225409)
1. Contemporary management of borderline resectable pancreatic ductal adenocarcinoma.
Lekka K; Tzitzi E; Giakoustidis A; Papadopoulos V; Giakoustidis D
Ann Hepatobiliary Pancreat Surg; 2019 May; 23(2):97-108. PubMed ID: 31225409
[TBL] [Abstract][Full Text] [Related]
2. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
Janssen QP; O'Reilly EM; van Eijck CHJ; Groot Koerkamp B
Front Oncol; 2020; 10():41. PubMed ID: 32083002
[TBL] [Abstract][Full Text] [Related]
4. Advances and Remaining Challenges in the Treatment for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
Sulciner ML; Ashley SW; Molina G
J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36013111
[TBL] [Abstract][Full Text] [Related]
5. Advances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades.
Taboada AGM; Lominchar PL; Roman LM; García-Alfonso P; Martin AJM; Rodriguez JAB; Pascual JMA
Ann Hepatobiliary Pancreat Surg; 2021 May; 25(2):179-191. PubMed ID: 34053920
[TBL] [Abstract][Full Text] [Related]
6. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma.
Trinh KV; Fischer DA; Gardner TB; Smith KD
Front Oncol; 2020; 10():1461. PubMed ID: 33042792
[No Abstract] [Full Text] [Related]
8. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
[TBL] [Abstract][Full Text] [Related]
9. Borderline resectable pancreatic cancer.
Hackert T; Ulrich A; Büchler MW
Cancer Lett; 2016 Jun; 375(2):231-237. PubMed ID: 26970276
[TBL] [Abstract][Full Text] [Related]
10. [Neoadjuvant treatment of primarily resectable and borderline resectable pancreatic cancer].
Scheufele F; Friess H
Chirurg; 2020 May; 91(5):391-395. PubMed ID: 31965198
[TBL] [Abstract][Full Text] [Related]
11. Conversion Surgery for Pancreatic Cancer-The Impact of Neoadjuvant Treatment.
Klaiber U; Hackert T
Front Oncol; 2019; 9():1501. PubMed ID: 31993372
[TBL] [Abstract][Full Text] [Related]
12. Surgery for Pancreatic Cancer after neoadjuvant treatment.
Hackert T
Ann Gastroenterol Surg; 2018 Nov; 2(6):413-418. PubMed ID: 30460344
[TBL] [Abstract][Full Text] [Related]
13. Borderline resectable pancreatic cancer: Certainties and controversies.
Nappo G; Donisi G; Zerbi A
World J Gastrointest Surg; 2021 Jun; 13(6):516-528. PubMed ID: 34194610
[TBL] [Abstract][Full Text] [Related]
14. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.
Kim NH; Kim HJ
Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):450-455. PubMed ID: 30237091
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Treatment in Resectable Pancreatic Cancer. Is It Time for Pushing on It?
Vivarelli M; Mocchegiani F; Nicolini D; Vecchi A; Conte G; Dalla Bona E; Rossi R; Benedetti Cacciaguerra A
Front Oncol; 2022; 12():914203. PubMed ID: 35712487
[TBL] [Abstract][Full Text] [Related]
16. Treatment of pancreatic cancer-neoadjuvant treatment in resectable pancreatic cancer (PDAC).
Seufferlein T; Ettrich TJ
Transl Gastroenterol Hepatol; 2019; 4():21. PubMed ID: 30976724
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Treatment in Pancreatic Cancer.
Oba A; Ho F; Bao QR; Al-Musawi MH; Schulick RD; Del Chiaro M
Front Oncol; 2020; 10():245. PubMed ID: 32185128
[TBL] [Abstract][Full Text] [Related]
18. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant treatment of pancreatic ductal adenocarcinoma: Whom, when and how.
Manojlovic N; Savic G; Manojlovic S
World J Gastrointest Surg; 2024 May; 16(5):1223-1230. PubMed ID: 38817288
[TBL] [Abstract][Full Text] [Related]
20. New challenges in perioperative management of pancreatic cancer.
Puleo F; Maréchal R; Demetter P; Bali MA; Calomme A; Closset J; Bachet JB; Deviere J; Van Laethem JL
World J Gastroenterol; 2015 Feb; 21(8):2281-93. PubMed ID: 25741134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
